NewsRoom Articles - Page 15 of 213

ThursdayApr 10, 2025 10:00 am

Health Insurance Shares Climb After Medicare Reimbursements are Boosted

Shares of health insurance firms in the U.S. jumped after the federal government announced a reimbursement rate increase which was higher than what had been expected by the industry. The rate increase applies to Medicare Advantage plans and will take effect next year. This increase was welcome news to the industry that had seen their margins squeezed by rising costs of medical care. Humana, an insurer specializing in Medicare, saw its shares soar by 16% while other firms, such as Centene, UnitedHealth Group and CVS saw upticks ranging from 5% to 10%. After the Covid-19 pandemic, there was a surge…

TuesdayApr 08, 2025 10:00 am

Study Shows the Gut is Key in Protecting the Brain After Stroke

Many patients who have had a stroke often suffer secondary brain damage as a result of the inflammation that is triggered during the stroke. Scientists have been working to find ways to forestall this secondary brain damage and a recent preclinical study conducted by a team at UTHealth Houston could provide a viable way to address neuroinflammation after stroke episodes. For their study, the team focused on molecules whose role is to bind to particular receptors. These molecules are called ligands, mainly produced in the gut. Ligands are vital in facilitating cell function and signaling between different parts of the…

TuesdayApr 08, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation

Recent Zacks report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix. The Zacks report underscores Soligenix's strategic focus on rare diseases and areas lacking effective treatments. Financially, Soligenix has demonstrated resilience amid the challenges inherent in biopharmaceutical development. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix's diverse product pipeline, financial health and strategic positioning within the biopharmaceutical industry.…

MondayApr 07, 2025 10:00 am

Study Uncovers Drivers of Brain Tumor Growth, Could Open New Treatment Approaches

A new study has uncovered key drivers of brain cancer growth that could make it possible to predict or even slow down the rate at which these tumors regrow. This could open a new chapter in personalized cancer treatment. The research team, led by Professor Parag Katira of San Diego State University, together with Moffit Cancer Center’s Ana Gomes and Noemi Andor, discovered how brain tumor cells grow and transform in response to the environment in which they find themselves. These findings could enable doctors to predict the cancer’s response to any treatments to be administered. The team focused their…

FridayApr 04, 2025 10:30 am

Adageis Offers Enhanced Transparency in Insurance Payments for Healthcare Providers

The company’s AI-driven software helps clinics transition to value-based care and optimize revenue streams, offering providers superior visibility into insurance contracts and associated reimbursements. Adageis provides advocacy for healthcare organizations, identifying discrepancies in payments and ensuring they are fairly compensated for services. The platform allows providers to assess which insurance contracts align best with their financial goals and patient care priorities, improving financial planning. Healthcare providers often struggle to navigate complex insurance contracts to determine whether they are receiving proper reimbursement for services. A lack of transparency in how the process unfolds can result in lost revenue and financial instability,…

ThursdayApr 03, 2025 10:00 am

Study Suggests Possible Link Between ADHD and Heightened Dementia Risk

ADHD, or attention deficit hyperactivity disorder, is usually diagnosed during one’s childhood, but more adults are being diagnosed with this condition. Experts have observed that among adults diagnosed with ADHD, the likelihood of developing dementia is heightened, but it hasn’t been clear why this is the case. Now a new study suggests a possible explanation for the increased possibility of dementia development among adult ADHD sufferers. A press release issued by Prof. Paul Unschuld, who initiated this study, indicates that while epidemiological studies indicated a heightened risk of dementia development among adults diagnosed with ADHD, the mechanisms behind this link…

ThursdayApr 03, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate,…

WednesdayApr 02, 2025 9:45 am

Clene Inc. (NASDAQ: CLNN) to Share CNM-Au8(R) Progress at Jones Las Vegas Conference

The company will present at the Jones Las Vegas Technology and Innovation Conference on April 8-9, to update investors on its lead drug candidate. The conference will provide one-on-one meetings and networking opportunities for institutional investors and executives. Clene recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS treatment. New analyses suggest CNM-Au8 improves survival for ALS patients, with a 4.1-month increase in restricted mean survival time. Clene plans to begin enrollment for a Phase 3 confirmatory trial (RESTORE-ALS) in mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical…

TuesdayApr 01, 2025 10:00 am

Study Explains Why Melanoma, Other Cancers Evade and Resist Immunotherapy

Cutaneous melanoma is the most aggressive skin cancer type and it is characterized by manifesting diverse mutations. Under normal circumstances, several of these mutations could be identified as threats by the immune system, but in this type of cancer, this doesn’t happen. Consequently, most patients are unresponsive to immunotherapy. This challenge has baffled oncology researchers for years. Now new research conducted by CNIO Melanoma Group located at the National Cancer Research Center in Spain has discovered the mechanism through which aggressive tumors like cutaneous melanoma evade the immune system in a way that isn’t expected. The study team, headed by…

FridayMar 28, 2025 1:00 pm

Adageis Simplifies Value-Based Care for Healthcare Providers

Adageis makes it easier for providers to identify and obtain the most profitable reimbursements while maintaining high-quality value-based care. The company’s platform enables providers to receive the full payments they deserve by advocating on their behalf with insurers. Adageis offers seamless integration – the platform works with over 90 electronic health record (“EHR”) systems, eliminating the need for disruptive system changes. The company is working with investors to develop new solutions to support small and independent healthcare practices. Healthcare providers often struggle with complex reimbursement structures, making it difficult to optimize cash flow while ensuring high-quality value-based patient care. Adageis…